| Forward-Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans,
strategies, timelines and expectations for the company’s operations, including its growth strategies, opportunities and expectations for 2025 and beyond; the company’s expectations regarding its estimated peak
revenue for AYVAKIT and the systemic mastocytosis market; continued growth in the breadth and depth of prescribing for AYVAKIT; the company’s development plans and expectations regarding BLU-808,
including its potential treatment for mast cell disorders, as well as other potential related allergic-inflammatory indications; expectations related to the markets for the company’s current or future approved drugs
and drug candidates, including expectations regarding the size or scale of patient opportunities that its current or future approved drugs and drug candidates; statements regarding anticipated clinical milestones;
the potential benefits of any of the company’s current or future approved drugs or drug candidates in treating patients; statements related to the company’s liquidity and capital position, product revenues, run-rate, financial performance, strategy, goals and anticipated milestones, business plans and focus, including expectations regarding its 2025 capital allocation strategy, its anticipated cash burn, and path to
profitability.
The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “opportunity,” “continue,” “target” and similar expressions are
intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this presentation are based on management’s
current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any
forward-looking statements contained in this presentation, including, without limitation: the risk that the marketing and sale of AYVAKIT/ AYVAKYT or any future approved drugs may be unsuccessful or less
successful than anticipated, or that AYVAKIT/ AYVAKYT may not gain market acceptance by physicians, patients, third-party payors and others in the medical community; the risk that the market opportunities
for AYVAKIT/ AYVAKYT or the company’s drug candidates are smaller than it estimates or that any approval it obtains may be based on a narrower definition of the patient population that it anticipates; the risk
of delay of any current or planned clinical trials or the development of the company’s current or future drug candidates; risks related to the company’s ability to successfully demonstrate the safety and efficacy of
its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the risk that preclinical and clinical results for the company’s drug candidates may not support further development of such
drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the risk that the timing of the initiation of clinical trials and
trial cohorts at clinical trial sites and patient enrollment rates may be delayed or slower than anticipated; the risk that actions of regulatory agencies may affect the company’s approved drugs or its current or
future drug candidates, including affecting the initiation, timing and progress of clinical trials; risks related to the company’s ability to obtain, maintain and enforce patent and other intellectual property protection
for its products and current or future drug candidates it is developing; risks related to the success of the company’s current and future collaborations, financing arrangements, partnerships, licensing and other
arrangements; risks related to the company’s liquidity and financial position, including the risk that it may be unable to generate sufficient future product revenues to maintain a self-sustainable financial profile
and to achieve profitability; and risks related to the accuracy of the company’s estimates of revenues, expenses and capital requirements. These and other risks and uncertainties are described in greater detail
in the section entitled “Risk Factors” in the company’s filings with the Securities and Exchange Commission (SEC), including the company’s most recent Annual Report on Form 10-K, as supplemented by its
most recent Quarterly Report on Form 10-Q and any other filings that the company has made or may make with the SEC in the future. The forward-looking statements in this presentation are made only as of the
date hereof, and except as required by law, the company undertakes no obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or
otherwise. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements.
This presentation also contains estimates, projections and other statistical data made by independent parties and by the company relating to market size and growth and other data about the company's industry.
These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of the company's future
performance and the future performance of the markets in which the company operates are necessarily subject to a high degree of uncertainty and risk.
Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation.
2 |
